References
- Dniker, B.J., Talpaz, M., Resta, D.J., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031–1037.
- Savage, D.G. and Antman, K.H. (2002) "Imatinib mesylate — a new oral targeted therapy", New England Journal of Medicine, 346, 683 — 693.
- Kantarjian, H.M., Sawyers, CL., Hochhaus, A., et al. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myeloid leukemia", New England Journal of Medicine, 346, 645–652.
- Lin, F., van Rhee, F., Goldman, J.M. and Cross, N.C.P. (1996) "Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation", Blood, 87, 4473 —4478.
- Djaldetti, M., Padeh, B., Pinkhas, J. and deVries, A. (1966) "Prolonged remission in chronic myeloid leukemia after one course of busulfan", Blood, 27, 103–109.
- Talpaz, M., Kantarjian, H.M., McCredie, KB., et al. (1986) "Hematologic remission and cytogenetic improvement induced by recombinant human interferonA in chronic myelogenous leukemia", New England Journal of Medicine, 314, 1065–1069.
- Ruiz-Argdelles, G.J. (2002) "What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?", Haematologica, 87, ELT15.